140 related articles for article (PubMed ID: 29925897)
1. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
2. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.
Fu R; Tong JS
J Cell Mol Med; 2020 Jul; 24(13):7600-7608. PubMed ID: 32410348
[TBL] [Abstract][Full Text] [Related]
3. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
4. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
[TBL] [Abstract][Full Text] [Related]
5. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
6. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
[TBL] [Abstract][Full Text] [Related]
7. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R; Akram S
Tumour Biol; 2016 Apr; 37(4):5413-26. PubMed ID: 26563369
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
12. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
[TBL] [Abstract][Full Text] [Related]
13. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H
Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559
[TBL] [Abstract][Full Text] [Related]
14. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
16. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
17. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
18. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
19. Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR.
Yang L; Higashisaka K; Shimoda M; Haga Y; Sekine N; Tsujino H; Nagano K; Shimazu K; Tsutsumi Y
Biochem Biophys Res Commun; 2022 Jan; 588():175-181. PubMed ID: 34959190
[TBL] [Abstract][Full Text] [Related]
20. BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR-665 and interacting with YAP1.
Ye X; Liu Q; Qin X; Ma Y; Sheng Q; Wu X; Chen S; Huang L; Sun Y
FASEB J; 2024 Apr; 38(7):e23589. PubMed ID: 38572594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
